# Artax Biopharma

**Canonical:** https://apis.io/providers/artax-biopharma/  
**Website:** https://artaxbiopharma.com  
**APIs profiled:** 1

Artax Biopharma is a Phase 2 clinical-stage biotechnology company dedicated to developing safe and effective treatments for autoimmune diseases. Their approach modulates T cell activation through Signal 1, aiming to prevent self-activation without causing immune suppression. The company has a pipeline of first‑in‑class Nck modulator candidates, with lead program AX‑158 showing promising biomarker and clinical data.

## Kin Score — 12.3 / 100 (emerging)

Scored 2026-10-23 under rubric 0.25.0. Trend: flat (+0.0 from 12.3).

| Facet | Score |
|---|---|
| Discoverability | 58.9 |
| Contract Quality | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 11.9 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 10.9 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |
| Pagination Ratio | na |
| Operation Distinctiveness | na |

## APIs (1)

- **Artax Biopharma API** — Artax Biopharma provides data on its pipeline and progress via a developer portal.

## Security (1)

- **Artax Biopharma Domain Security** — TLSv1.3 · DMARC

## Tags

Biotechnology, Clinical Stage, Autoimmune, Immunomodulation, Nck-modulators

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/artax-biopharma/). Scores are computed from the provider's own public artifacts under a published rubric.